LGD-4033 + YK-11

This entry describes a research stack combining two distinct compounds. LGD-4033, also called Ligandrol, is a non-steroidal selective androgen receptor modulator (SARM) that binds the androgen receptor with high affinity and tissue selectivity and is among the best-studied SARMs in humans ^[1]. YK-11 is a synthetic steroidal compound, structurally derived from dihydrotestosterone, that acts as an androgen-receptor partial agonist and is popularly described as a myostatin inhibitor because it raises levels of follistatin ^[2][4].

LGD-4033 has been evaluated in a placebo-controlled clinical study in healthy young men, in which it was well tolerated over a short course and increased lean body mass without a change in prostate-specific antigen ^[1]. YK-11's evidence base is preclinical: in cultured muscle cells it induced myogenic differentiation and increased follistatin more strongly than dihydrotestosterone did ^[2], and in bone-forming cells it promoted osteoblast proliferation and differentiation ^[3]. Because YK-11 is a non-approved experimental substance, analytical chemists have also mapped its metabolism to support anti-doping detection ^[4].

The rationale for combining the two is mechanistic complementarity: the SARM provides androgen-receptor-driven anabolic signaling while YK-11 aims to release muscle from the restraining influence of myostatin. Neither compound is an approved medicine, and there are no controlled human data on the specific combination; both are sold as research chemicals and are prohibited in sport. Anyone considering such stacks should understand that the pairing amplifies both the intended anabolic signal and the associated risks ^[1][4].

This stack carries the combined risks of both compounds and has never been tested together in humans. Expect meaningful suppression of natural testosterone, so recovery of the hormone axis becomes a real concern; drops in HDL cholesterol; and raised liver enzymes, with YK-11 in particular flagged for liver strain given its methylated steroid-like structure. There is no approved medical use, both are banned by WADA, and products are unregulated research chemicals with uncertain dose and purity. Bloodwork and a recovery plan are the least people do. Not intended for human use.

This research stack unites two compounds with distinct origins. LGD-4033, also called ligandrol, was developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics; it advanced further than most SARMs, reaching an early placebo-controlled human study that showed dose-dependent gains in lean body mass over three weeks. YK-11, by contrast, is a steroidal compound first described by the Japanese researcher Yuichiro Kanno and coworkers around 2011, notable for activating the androgen receptor while also inducing follistatin, a natural antagonist of the muscle-limiting protein myostatin.

The pairing of the two is not a formally developed pharmaceutical product but a combination assembled within the research-chemical community to engage muscle growth through two converging routes at once. Neither the individual agents nor the stack has been approved for human use, and both are prohibited in sport; much of the published work on YK-11 in fact comes from anti-doping laboratories characterizing the compound and its metabolites for detection. The stack therefore exists at the experimental frontier of anabolic research rather than in established medicine.

The LGD-4033 + YK-11 combination has an outsized reputation among those exploring maximal anabolic signaling, precisely because it attacks muscle growth from two different directions: LGD-4033 amplifies androgen-receptor drive while YK-11 raises follistatin to release the myostatin brake. LGD-4033's early human data, showing a dose-dependent rise in lean mass, lend the pairing a degree of credibility unusual for research compounds, and YK-11's follistatin mechanism gives it a genuinely distinctive scientific rationale.

It is a frequently discussed and potent-sounding stack for that reason. Honesty requires emphasizing that no human study has evaluated the two together, that YK-11's steroidal structure raises concern for hepatic strain, and that both suppress the body's own testosterone and shift lipids such as HDL cholesterol. This is a compelling mechanistic pairing that remains firmly investigational, and its risk profile is only partially understood.